Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (2) : 127-133     DOI: 10.1007/s11684-011-0137-7
Developments in cancer prevention and treatment using traditional Chinese medicine
Hongsheng Lin(), Jie Liu, Ying Zhang
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
Download: PDF(115 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Through the joint efforts of several generations of practitioners in traditional Chinese medicine (TCM) and integrated medicine of oncology, we have made some achievements in cancer treatment using TCM in over 50 years, including treatment concepts, methods, and basic and clinical research. Currently, TCM plays an indispensable role in cancer prevention and treatment. However, we also clearly recognize that there are some issues that have yet to be resolved. In the future, cancer treated with TCM will face unprecedented opportunities and challenges. This article reviews the developments of TCM in the treatment of cancer.

Keywords traditional Chinese medicine (TCM)      cancer     
Corresponding Authors: Lin Hongsheng,   
Issue Date: 05 June 2011
URL:     OR
StageKey principlesMain purposes
PrecancerousEliminate the evil factorsPrevent tumorigenesis
Cancer initial treatmentPresurgery: strengthen the body resistanceEnhance the efficacy and reduce the toxicity of conventional treatments
After-surgery: nourish Qi, promote blood circulation, detoxify
During chemotherapy: reinforce the spleen and kidneys as well as tonify the blood and Qi
During radiotherapy: nourish Qi and Yin, activate blood, and detoxify
Tumor remission or stabilizationStrengthen body resistance and eliminate the evil factorsPrevent recurrence or metastasis and disease progression, and prolong survival
Without indications of conventional treatments or End stageGood performance status: eliminate the evil factors (Quxie) and support vital Qi (Fuzheng) as supplementImprove QOL and prolong survival
Moderate performance status: Give equal stress to Fuzheng and Quxie
Poor performance status: Fuzheng and Quxie as supplement
Tab.1  TCM treatment strategies for cancer patients
1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010. Available from:
2 Han YY, Feng P, Wen ZhY. Research development on Chinese herbs of anticancer. J Beijing TCM (Bei Jing Zhong Yi) 2003; (2):45–48 (in Chinese)
3 Gao WB. Research development on Chinese herbs of anticancer. Med J Liaoning (Liao Ning Yi Yao) 1977; (6): 29–33 (in Chinese)
4 Tian JZh. Pharmacological classification and clinical significance of anti-cancer Chinese herbs. J Shandong College Tradit Chin Med (Shan Dong Zhong Yi Xue Yuan Xue Bao) 1986; 10(2): 16–19 (in Chinese)
5 Tang MX, Yu GQ, Duan FW. An antitumorigenic study by a TCM formula belonging to the category of enhancing the righteousness and consolidating the foundation. Chin J Cancer (Ai Zheng) 1986; 5(1): 65–69 (in Chinese)
6 Zhang DZh, Xu JD, Li PW, Dong XR, Hao YX, Li X, Cai GR, Cui HJ, Wan DG, Zhou W, Yu GQ. Clinical and experimental researches on improving radiation sensibility for lung cancer patients by “Fu Zheng Zeng Xiao”(FZ). Chin J Surg of Integr Tradit West Med (Zhongguo Zhong Xi Yi Jie He Wai Ke Za Zhi) 1998; 4(2): 71–75 (in Chinese)
7 Liu JX, Xu ZY, Shi ZM, Guo YH, Fan ZhZ, Li MH, Huang JM, Zhu YW, Zhao LH, Shi ChM, Gao H, Chen SX. Prospective study on Fuzheng treatment in 122 advanced non-small cell lung cancer patients. China J Tradit Chin Med Pharm(Zhongguo Yi Yao Xue Bao) 1987; 2(1): 12–16 (in Chinese)
8 Pan MJ, Li YH, Chen LF. Observation of the long term curative effect of 150 cases of nasopharyngeal cancer treated with Fu Zheng Sheng Jin decoction and radiotherapy. J Integr Tradit West Med(Zhong Xi Yi Jie He Za Zhi) 1985; 5(2): 83–85 (in Chinese)
9 Cai WM, Hu YH, Zhang HX, Xu GZh, Qin DX, Wu XL, Yan JH, Gu XZh. Prospective controlled trial of nasopharyngeal carcinoma treated with traditional Chinese medicine and radiation therapy. J Tradit Chin Med (Zhong Yi Za Zhi) 1983; (9): 36–38 (in Chinese)
10 Zhang DZh. Integrated traditional Chinese medicine and western medicine in advanced lung cancer. J China-Japan Friendship Hosp(Zhong Ri You Hao Yi Yuan Xue Bao) 1987; 1(1): 33–37 (in Chinese)
11 Liu LM, Lin ShY, Wu LC, Wang ZS, Zhou WSh, Guo Y, Shen MH, Yang WH. Xie ChSh. Clinical observation on the synergic and detoxified action of injection of Radix Codonopsis and Radix Ophiopogonis in chemotherapy of lung cancer. J Tradit Chin Med (Zhong Yi Za Zhi)1994; 35(5): 280–282 (in Chinese)
12 Sun GZh, Wang GM, Chen ChH, Song L, Zhang PT, Pan XM, Hou W, Zhang PY, Yang ZY. YGQ. Clinical and experimental study on treatment of advanced gastrointestinal carcinoma with FuzhengFangai oral liquid combined with chemotherapy. Chin J Surg of Integr Tradit West Med (Zhonguo Zhong Xi Yi Jie He Wai Ke Za Zhi)1995; 1(5): 266–270 (in Chinese)
13 Fang XX, Wang ShH, Li LQ, Wang L. Observation of treatment with integrative medicine to reduce chemotherapy-induced leukocyte and platelet in 168 patients. J Clin Oncol (Lin Chuang Zhong Liu Xue Za Zhi) 1997; 2(3): 56 (in Chinese)
14 Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z, Liu M. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010; 31(12): 2097–2104
doi: 10.1093/carcin/bgq167 pmid:20732905
15 Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328(5975): 240–243
doi: 10.1126/science.1183424 pmid:20378816
16 Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68(11): 4347–4351
doi: 10.1158/0008-5472.CAN-07-2970 pmid:18519695
17 Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005; 106(7): 2409–2416
doi: 10.1182/blood-2005-03-0854 pmid:15956285
18 Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, Hsieh SC, Hsiao PW. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 2009; 15(17): 5435–5444
doi: 10.1158/1078-0432.CCR-09-0298 pmid:19690196
19 Lin HS, Li ShQ, Piao BK. Effective evaluation methods for treatment with traditional Chinese medicine in advanced lung cancer. Bull Chin Cancer (Zhongguo Zhong Liu) 2000; 9(8): 354–355 (in Chinese)
20 Zhang PT, Yu MW, Yang ZY, Li DR, Liu YH, Lin HSh. Compared study on effective evaluation methods of TCM and WM in advanced non-small cell lung cancer. J Integr Tradit West Med (Zhong Xi Yi Jie He Za Zhi) 2010; 30(7): 702–705 (in Chinese)
21 Lin LZh, Lan ShQ, Zhou DH. A discussion on the criterion of therapeutical effect of malignant tumor(solid carcinoma) in TCM. New J Tradit Chin Med (Xin Zhong Yi) 2001; 33(8): 5–6 (in Chinese)
22 Sun HY, Xing YM, Li YW, Liu DY, Xie GR. Quality evaluation of randomized controlled trails in Chinese medicine combined with chemotherapy in non-small cell lung cancer. 3rd International Congress of TCM and Integrated TCM-WM Oncology. 2010, 84–85 (in Chinese)
23 Lin HSh, Zhang Y. Evidence-based medical study of TCM on non-small cell lung cancer. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2008;(4): 121–125 (in Chinese)
24 Sun Y, Lin H, Zhu YZH, Feng JF, Chen ZhT, Li GS, Zhang XR, Zhang ZQ, Tang JF, Shi MQ, Hao XZH, Han H. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Zhongguo Fei Ai Za Zhi) 2006; 9(3): 254–258 (in Chinese)
25 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer V.2. 2009.Available from:
26 Zheng ChS, Chen LW, Huang Q, Hu J, Du J, Xu XJ. Establishment of computer simulation analysis for Multi-target anti-tumor effect of Chinese medicine. J Fujian College Tradit Chin Med (Fu Jian Zhong Yi Xue Yuan Xue Bao) 2007; 17(3): 37–40 (in Chinese)
27 Wu Q, Bi ZhM, Li P, Qi LW. Advances in biological screening-chemical analysis of the bioactive components in traditional Chinese medicines based on holistic characteristics. J China Pharm Univ (Zhongguo Yao Ke Da Xue Xue Bao) 2007; 38(4): 289–293 (in Chinese)
28 Hao H, Cui N, Wang G, Xiang B, Liang Y, Xu X, Zhang H, Yang J, Zheng C, Wu L, Gong P, Wang W. Global detection and identification of non-target components from herbal preparations by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a strategy. Anal Chem 2008; 80(21): 8187–8194
doi: 10.1021/ac801356s pmid:18795791
29 Zhou XZh, Liu BY, Yao NL, Chen SB, Li P,Wang YH,Zhang RSh. Studies and Applications: TCM Clinical Data Warehouse and Associated Data Mining Platform. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2007; 9(4): 74–80 (in Chinese)
30 Liu J, Lin HSh, Hou W, Li DR, Zhou XZh. Pilot study on the characteristics of Chinese medicine treatment in lung cancer patients by use of data mining methods. World Sci Technol—Modernization Tradit Chin Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2009; 11(5): 753–757 (in Chinese)
31 Investment Advisor in the Industry Research Center. 2010–2015 Investment Analysis of Chinese medicine industry and Forecast Report. 2010,5. Available from:
32 Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22(12): 2489–2503
doi: 10.1200/JCO.2004.08.182 pmid:15197212
33 Gan T, Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2010; (1): CD005096
34 Wei X, Chen Z, Yang X, Wu T. Chinese herbal medicines for esophageal cancer. Cochrane Database Syst Rev 2009; (4): CD004520
35 McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006; 24(3): 419–430
doi: 10.1200/JCO.2005.03.6392 pmid:16421421
[1] Yiming Ma,Ting Xiao,Quan Xu,Xinxin Shao,Hongying Wang. iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer[J]. Front. Med., 2016, 10(3): 278-285.
[2] Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature[J]. Front. Med., 2016, 10(2): 191-203.
[3] Alexandra Urman,H. Dean Hosgood. Curbing the burden of lung cancer[J]. Front. Med., 2016, 10(2): 228-232.
[4] Chunxiao Li,Haijuan Wang,Feng Lin,Hui Li,Tao Wen,Haili Qian,Qimin Zhan. Bioinformatic exploration of MTA1-regulated gene networks in colon cancer[J]. Front. Med., 2016, 10(2): 178-182.
[5] Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao. CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes[J]. Front. Med., 2016, 10(2): 204-211.
[6] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[7] Aixiu Qiao,Feng Gu,Xiaojing Guo,Xinmin Zhang,Li Fu. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications[J]. Front. Med., 2016, 10(1): 33-40.
[8] Dan Wu,Qingxun Hu,Yizhun Zhu. Therapeutic application of hydrogen sulfide donors: the potential and challenges[J]. Front. Med., 2016, 10(1): 18-27.
[9] Hualiang Lin,Bofu Ning,Jihua Li,Guangqiang Zhao,Yunchao Huang,Linwei Tian. Temporal trend of mortality from major cancers in Xuanwei, China[J]. Front. Med., 2015, 9(4): 487-495.
[10] Yinyin Xie,Yuanliang Zhang,Lu Jiang,Mengmeng Zhang,Zhiwei Chen,Dan Liu,Qiuhua Huang. Disabled homolog 2 is required for migration and invasion of prostate cancer cells[J]. Front. Med., 2015, 9(3): 312-321.
[11] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[12] Daniel Wai-Hung Ho,Alan Ka-Lun Kai,Irene Oi-Lin Ng. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma[J]. Front. Med., 2015, 9(3): 322-330.
[13] Lingqiang Zhang,Runchen Miao,Xiude Zhang,Wei Chen,Yanyan Zhou,Ruitao Wang,Ruiyao Zhang,Qing Pang,Xinsen Xu,Chang Liu. Exploring the diagnosis markers for gallbladder cancer based on clinical data[J]. Front. Med., 2015, 9(3): 350-355.
[14] Li Bian,Yonghua Ruan,Liju Ma,Hairong Hua,Li Zhou,Xiaoyu Tuo,Zheyan Zhou,Ting Li,Shiyue Liu,Kewei Jin. Pathogenesis sequences in Gejiu miners with lung cancer: an introduction[J]. Front. Med., 2015, 9(3): 344-349.
[15] Peter B. Alexander,Xiao-Fan Wang. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies[J]. Front. Med., 2015, 9(2): 134-138.
Full text